The Accelerated Approval of Oncologic Drugs
Authors:
- 22 January 2014
- journal article
- viewpoint
- Published by American Medical Association (AMA) in JAMA
- Vol. 311 (4) , 353-354
Abstract
On October 31, 2013, the US Food and Drug Administration (FDA) suspended marketing and sales of the BCR-ABL tyrosine kinase inhibitor ponatinib (Iclusig, AriadKeywords
This publication has 4 references indexed in Scilit:
- A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2013
- Reevaluating the Accelerated Approval Process for Oncology DrugsClinical Cancer Research, 2013
- Ponatinib in Refractory Philadelphia Chromosome–Positive LeukemiasNew England Journal of Medicine, 2012
- Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsBlood, 2007